Despite similarities between adult psoriasis and pediatric psoriasis, pediatric psoriasis presents a challenge for patients seeking effective long-term therapy. Thetreatments available forpediatric psoriasis are limited. Topical corticosteroids are associated with more-frequent, severe adverse events in children, and only two biologics, Amgen’s Enbrel and Janssen's Stelara, are approved for pediatric and adolescent psoriasis, respectively. Topical corticosteroids continue to dominate treatment; biologics, although used in later lines of therapy, are increasingly being used, reflecting physicians’ growing acceptance of this drug class. Use of conventional systemics appears to be on the decline, underscoring theneed for treatments with more-acceptable safety profiles.
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed pediatric psoriasis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric psoriasis patients?
- How have biologics such as Humira, Enbrel, and Stelara been integrated into the treatment algorithm?
- What proportion of pediatric psoriasis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of pediatric psoriasis patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients with pediatric psoriasis?